After 30 years, the first endothelin-receptor antagonist (Aprocitentan) is approved for the treatment of arterial hypertension

被引：0
|
作者：
Tamargo, Juan [1 ]
机构：
[1] Univ Complutense, Sch Med, Dept Pharmacol & Toxicol, Plaza Ramon y Cajal S-N, Madrid 28040, Spain
来源：
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY | 2024年 / 10卷 / 05期
关键词：
D O I：
10.1093/ehjcvp/pvae035
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：371 / 373
页数：3
相关论文
共 50 条
  • [1] Aprocitentan (a Dual Endothelin-Receptor Antagonist) for Treatment-Resistant Hypertension
    McCoy, Emily K.
    Lisenby, Katelin M.
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2021, 77 (06) : 699 - 766
  • [2] Sitaxsentan - A new endothelin-receptor antagonist for the treatment of pulmonary arterial hypertension
    Reinhart, Kurt
    White, C. Michael
    [J]. FORMULARY, 2007, 42 (05) : 295 - +
  • [3] Endothelin-Receptor Antagonist Treatment of Portopulmonary Hypertension
    Hinterhuber, Lukas
    Graziadei, Ivo W.
    Kaehler, Christian M.
    Jaschke, Werner
    Vogel, Wolfgang
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2004, 2 (11) : 1039 - 1042
  • [4] Resistant arterial hypertension: endothelin antagonist aprocitentan convinces
    Franke, Katharina
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2023, 148 (11) : 662 - 662
  • [5] The endothelin-receptor antagonist bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects
    Sitbon, O
    Beghetti, M
    Petit, J
    Iserin, L
    Humbert, M
    Gressin, V
    Simonneau, G
    [J]. EUROPEAN HEART JOURNAL, 2004, 25 : 22 - 22
  • [6] Aprocitentan Dual endothelin ETA/ETB receptor antagonist Treatment of resistant hypertension
    Warden, B. A.
    Duell, P. B.
    [J]. DRUGS OF THE FUTURE, 2021, 46 (08) : 595 - 611
  • [7] Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension
    Angeli, Fabio
    Verdecchia, Paolo
    Reboldi, Gianpaolo
    [J]. CARDIOLOGY AND THERAPY, 2021, 10 (02) : 397 - 406
  • [8] Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension
    Fabio Angeli
    Paolo Verdecchia
    Gianpaolo Reboldi
    [J]. Cardiology and Therapy, 2021, 10 : 397 - 406
  • [9] Use of oral endothelin-receptor antagonist bosentan in the treatment of portopulmonary hypertension
    Halank, M
    Miehlke, S
    Hoeffken, G
    Schmeisser, A
    Schulze, M
    Strasser, RH
    [J]. TRANSPLANTATION, 2004, 77 (11) : 1775 - 1776
  • [10] Endothelin-receptor antagonists in therapy of pulmonary arterial hypertension
    Ghofrani, H. A.
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2009, 134 : S177 - S178
12345